Plumbers, electricians and welders will be in huge demand as part of a national plan to train people for an extra 400,000 green jobs in the next five years, Ed Miliband has said.
The energy secretary revealed a new scheme to double those working…
Category: 6. Business
-
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC
Perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) with radical cystectomy and standard pelvic lymph node dissection (RC + PLND) significantly improved event-free survival (EFS), overall survival (OS), and pathologic…
Continue Reading
-
Neoadjuvant T-DXd Plus THP Yields pCR Benefit in High-Risk, HER2+ Early Breast Cancer
Neoadjuvant treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) followed by paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) led to an improvement in pathologic complete response (pCR) rate compared with dose-dense…
Continue Reading
-
From Mutation to Medicine: Targeted Therapies in Lung Cancer
Decades of clinical research has led to the discovery of key biomarkers, development of novel agents, and the subsequent improvement in patient survival outcomes.
At the European Society for Medical Oncology 2025 Congress, Jürgen Wolf, MD,…
Continue Reading
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and after Surgery – UroToday
- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and after Surgery UroToday
Continue Reading
-
Tiragolumab Plus Atezolizumab Fails to Improve Outcomes as Consolidation in NSCLC | Targeted Oncology
Consolidation therapy with tiragolumab plus atezolizumab (Tecentriq) failed to meet the primary end point of improving independent review facility (IRF)-assessed progression-free survival (PFS) vs standard durvalumab (Imfinzi) in patients with…
Continue Reading
-
Global AI Competition Could Create Trillion-Dollar Winners
Artificial intelligence (AI) represents a major opportunity for businesses across industries to develop products faster and cheaper than ever before. The race to gain a data-driven edge on the competition is fueling massive investment…
Continue Reading
-
T-DXd Superior to T-DM1 in Improving IDFS/DFS in Residual HER2+ Breast Cancer | Targeted Oncology
Interim data from the phase 3 DESTINY-Breast05 trial (NCT04622319) shared at the 2025 European Society for Medical Oncology (ESMO) Congress showed improved invasive disease–free survival (IDFS) with fam-trastuzumab deruxtecan-nxki (T-DXd;…
Continue Reading
-
Invikafusp Alfa Boasts High Disease Control Rate in Checkpoint Inhibitor–Resistant Solid Tumors
Invikafusp alfa led to tumor regression in target lesions in 52% of patients with tumor mutational burden–high (TMB-H) or microsatellite instability–high (MSI-H) solid tumors resistant to immune checkpoint blockade, according to data from…
Continue Reading
-
Pembrolizumab Plus Paclitaxel +/– Bevacizumab Yields Survival Advantages in Recurrent PROC
The combination of pembrolizumab (Keytruda) plus weekly paclitaxel with or without bevacizumab (Avastin) generated a statistically significant progression-free survival (PFS) benefit vs placebo plus paclitaxel with or without bevacizumab…
Continue Reading